Table 2.
IGF-1 and GH levels at the study visit in patients treated with lanreotide autogel 120 mg
| Number of patients (%) | Mean (SD) | |
|---|---|---|
| IGF-1 (μg/L) | 109 (100%) |
175.0 (74.5); 95% CI: 160.80–89.10 |
| IGF-1 valuesa | ||
| Normal | 100 (91.7%) | n/a |
| High | 9 (8.3%) | |
| Time elapsed since the last dose of lanreotide autogel, weeks | 101 | 7.6 (5.9) |
| Time elapsed from the blood test to the visit, days | 109 | 22.7 (25.4) |
| GH (ng/mL) | 108 (99.1%) | 2.1 (5.1) |
| GH ≤ 2.5 ng/mL | ||
| Yes | 87 (80.6%) | n/a |
| No | 21 (19.4%) | |
| GH ≤ 1.0 ng/mL | ||
| Yes | 63 (58.3%) | n/a |
| No | 45 (41.7%) | |
| GH (ng/mL) | ||
| ≤1.0 | 63 (58.3%) | n/a |
| >1 and ≤ 2.5 | 24 (22.2%) | |
| >2.5 | 21 (19.4%) | |
| GH level (ng/mL) in patients with normal IGF-1 levels | ||
| ≤1.0 | 59 (59.6%) | n/a |
| >1.0–≤2.5 | 22 (22.2%) | |
| >2.5 | 18 (18.2%) | |
n/a not applicable, SD standard deviation, CI confidence intervals
aIGF-1 levels were classified as normal or high by the treating physician based on the patient’s age and sex